Annual report pursuant to Section 13 and 15(d)

Deferred Royalty Obligation related to the Sale of Future Royalties - Schedule of Royalty Obligation transaction (Details)

v3.24.1
Deferred Royalty Obligation related to the Sale of Future Royalties - Schedule of Royalty Obligation transaction (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
Deferred Royalty Obligation [Line Items]  
Deferred royalty obligation related to the sale of future Vaxcyte royalties, net $ 149,114
Vaxcyte, Inc. ('Vaxcyte")  
Deferred Royalty Obligation [Line Items]  
Proceeds from the sale of future Vaxcyte royalties 140,000
Issuance costs (3,792)
Non-cash interest expense associated with the sale of future Vaxcyte royalties 12,570
Amortization of issuance costs 336
Deferred royalty obligation related to the sale of future Vaxcyte royalties, net $ 149,114